About Us

Cornerstone Pharmaceuticals is Innovating through Metabolic Science and by Empowering Immunity.

Cornerstone addresses significant unmet needs with therapies for hard-to-treat cancers. Cornerstone’s lead compounds, CPI 613® (devimistat) and CB 839 (telaglenastat), are undergoing multiple clinical trials in pancreatic cancer, biliary tract cancer etc.

Devimistat and teleglenastat, are currently undergoing preclinical studies for the treatment of biliary tract cancer, pancreatic cancer, head and neck and ovarian cancer etc. These studies aim to assess the effectiveness and safety of the drug combination. Additionally, there are plans to explore the potential benefits and scope of utilizing this drug combination further.

Devimistat has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the following indications: pancreatic cancer, Acute myeloid leukemia (AML), Burkitt’s lymphoma, biliary tract cancer, soft tissue sarcoma, myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma. In addition, the European Medicines Agency (EMA) has granted orphan drug designation to devimistat for Burkitt’s lymphoma, biliary Tract Cancer, pancreatic cancer, and AML.

For more information about our clinical trials, please visit our pipeline page.